10.25.19 - Today "Emerald Organic Products to License

New Post Public Reply Private Reply Replies (1) Message Board
Mauibound
805
10.25.19 - Today

"Emerald Organic Products to License Therapeutics Portfolio from Amarantus Bioscience Holdings"

Portfolio includes treatments for Alzheimer's disease, ADHD, Parkinson's disease, vision loss and severe burns Amarantus to receive Emerald Organics Preferred Stock for the

exclusive worldwide license

Emerald Organic CEO Ian Parker: "Emerald Organic will bring breakthrough therapies - and hope - to burn victims and those suffering from Alzheimer's and Parkinson's."

NEW YORK, Oct. 25, 2019 /PRNewswire/ -- Emerald Organic Products, Inc. and Amarantus Bioscience Holdings today announced a principal agreement for the

exclusive, worldwide license

of several cutting-edge treatments, including Phase 3-ready therapies for ADHD and skin regeneration.

Under the terms of the agreement, Emerald Organic (OTC: EMOR), a health science company that is a market leader in CBD products,

will license the therapeutic portfolio from Amarantus Holdings (OTC: AMBS)

in exchange for Emerald preferred stock and on-going, sales-based royalties. The preferred stock will convert into 50 million shares of common stock on April 30, 2022, with a non-stock, accelerated royalty based on sales if the common shares are below $100 million at the time of conversion.


"Emerald believes in the powerful healing ability of the body and has smartly invested in products and companies that have life-changing potential," said Ian Parker, CEO of Emerald Organic Products. "Amarantus' revolutionary therapies do exactly that – bringing hope and relief to long-suffering victims. Together, we see this acquisition as the first step toward combining consumer cannabis-based products and FDA-regulated drugs to improve outcomes for patients."

Specifically, Emerald Organic is

licensing the following therapies:

Eltoprazine: Emerald Organic intends to bring to market Phase 3-ready eltoprazine for the treatment of ADHD. The treatment of ADHD works by activating specific serotonin receptors in the brain, leading to a calming effect that has resulted in a positive Phase 2 trial result.

Skin Regeneration: Emerald Organic will also bring to market a Phase 3-ready Engineered Skin Substitute, a life-saving treatment for pediatric burn victims that could be used in a large number of skin replacement procedures. 

MANF: Emerald will also develop a treatment for neurodegeneration in the eyes. The unique neurotrophic factor repairs damaged neuronal cells and serves as a potential solution for retinal-and dopaminergic cell death. MANF may serve as a treatment for Glaucoma, macular degeneration, Parkinson's disease and the orphan diseases Wolfram's Syndrome and retinitis pigmentosa.

Amarantus CEO Gerald Commissiong said, "This opportunity allows us to leverage Emerald Organic's platform to bring our critical therapeutics to market. Not only will we drive value to our investors and shareholders, but we will deliver meaningful treatments and hope for patients. We are proud to begin working with Emerald Organic to continue to develop these pioneering medical treatments."



Also in the PR today put out by Emerald Organic

The transaction, which was led by boutique investment bank Advisory Group Equity Services, Ltd. (dba RHK Capital), is expected to become effective in the fourth quarter of 2019 and is subject to customary conditions and the receipt of consents from certain Amarantus stakeholders. Key Amarantus personnel will move over to incubate Emerald's emerging life sciences division.


Sounds like they are further along in the process than what is being understood.

In yesterday's PR (10.24.19)
today announced it has entered into a binding term sheet to license its therapeutic assets to Emerald Organic Growth, Inc. 

"Concurrent with this announcement, Amarantus and Coeptis Pharmaceuticals have mutually agreed to terminate the pending merger of Elto Pharma and Coeptis."

The "agreement" is not a non-binding nor is it an LOI.

It sounds like Gerald needed something concrete before terminating any "deeal" he was working on with Coeptis.

As for the wording in yesterday's PR about
"Pursuant to the agreement, upon certain conditions, Emerald intends to initiate a tender offer to acquire all outstanding shares of Amarantus"

There are AS and OS. Could it be that Emerald will make an offer to buy all OS while leaving Amarantus whatever AS they still have.

I haven't heard of that before, but is it impossible?

Amarantus will still own roughly 45% of the combined joint venture with Todos Medical, Ltd. 


Now, will there be a deal to be had for Emerald to buy the roughly 45%...

No clue on that either.

As we have seen, things can change. And drastically too.

Yes, there is still a lot to be seen, but as I read it, this deal is further along than what is being perceived seeing part of the deal is in written about in the past tense and it also is a binding
agreement.

I do not believe we will be hovering around 2 cents for much longer....

But that's just my 2 cents.

Aloha

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 50

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

Luca Mining Welcomes New VP to Boost Corporate Development

Updated Category News Views 123

Luca Mining Corp. Strengthens Leadership Team Luca Mining Corp. (TSXV: LUCA) (OTCQX: LUCMF) is thrilled to announce a strategic addition to its team with the appointment of Mr. Adam Melnyk as Vice President of Corporate Development. This move is set to elevate the company’s business development initiatives and drive growth as it aims to expand its operations in the...

Continue Reading
Sapiens Powers Insurance Innovation at Global Client Conference

Updated Category News Views 149

Sapiens Hosts Global Client Conference to Transform Insurance This event unites insurance leaders to exchange ideas for growth, adaptability, and impactful business strategies. Sapiens International Corporation (NASDAQ: SPNS) recently held its annual International Client Conference, gathering insurance professionals, prospects, and partners for three days of insightful...

Continue Reading
Elon Musk's Rising Influence in Trump's Circles on Social Media

Updated Category News Views 174

Elon Musk's Transformation into a Political Influencer Elon Musk, renowned for his groundbreaking ventures, has recently emerged as a key advocate for former President Donald Trump. Through his platform X, formerly known as Twitter, Musk is significantly amplifying conservative viewpoints. A Shift in Political Engagement Musk’s political activity has noticed a marked...

Continue Reading
Enphase Energy's Earnings: A Potential Turnaround Amid Setbacks

Updated Category News Views 82

Enphase Energy's Earnings Anticipation Enphase Energy Inc. (NASDAQ: ENPH) is preparing to announce its third-quarter earnings. The anticipated earnings per share stand at 77 cents, with expected revenue reaching approximately $391.98 million. Despite these expectations, investor sentiment appears to be less than optimistic. This solar energy company has faced significant...

Continue Reading
Is the 'Sell America 2.0' Trend Resurfacing in the Market?

Updated Category News Views 120

Market Update: Examining Leadership Shifts As global yields rise, US megacaps face pressure as investors revisit the 'Sell America' strategy. Notably, the S&P 500 has recently broken important technical levels, with noticeable fatigue in tech, media, and telecom leadership. On the other hand, diversification appears to be paying off, as small caps, foreign equities, and...

Continue Reading